13-cis-retinoic acid

DRUG5 trials

Sponsors

Eastern Cooperative Oncology Group, St. Jude Children's Research Hospital, United Therapeutics, Peter Zage, BeiGene

Conditions

High-risk NeuroblastomaLung CancerNeuroblastomaPrimary Refractory NeuroblastomaSolid Tumor

Phase 1

Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors

RecruitingNCT03611595

Peter ZageSolid Tumor

Start: 2018-08-28End: 2027-08-31Target: 18Updated: 2025-08-28

Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma

CompletedNCT05373901

BeiGeneHigh-risk Neuroblastoma

Start: 2022-06-07End: 2023-06-29Updated: 2024-10-04

Phase 2

Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer

CompletedNCT00062010

Eastern Cooperative Oncology GroupLung Cancer

Start: 2004-05-26End: 2012-08-31Updated: 2023-07-07

Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma

TerminatedNCT00808899

St. Jude Children's Research HospitalNeuroblastoma

Start: 2008-12-31End: 2009-07-31Updated: 2017-05-30

A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients

TerminatedNCT00969722

United TherapeuticsPrimary Refractory Neuroblastoma

Start: 2009-08-31Updated: 2013-03-08